Global Autoinjector Market
Global Autoinjector Market

Autoinjector Comprehensive Study by Type (Disposable Autoinjectors, Reusable Autoinjectors (Prefilled, and Empty)), Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Others Therapies), Route of Administration (Subcutaneous, Intramuscular), End User (Home Care Settings, Hospitals & Clinics, Ambulatory Care Settings) Players and Region - Global Market Outlook to 2026

Autoinjector Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 210 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Autoinjector Market Scope?
The autoinjector is a syringe with a spring-charged needle having a pre-charged dosage of drugs. The system triggers and administers a measured dosage of a drug when pressed into the body with a sliding motion. Autoinjectors are widely used for epinephrine self-administration; by migraine sufferers (for immediate pain relief); or for medical and emergency treatments. Auto-injectors provide multiple benefits such as decreasing needle-related phobia disorder, decreasing risks of a needle stuck accidents, ensuring dosage quality continuity, and helping increase effectiveness. This has led to significant growth of the global auto-injector market in the forecast period.

The Autoinjector market study is being classified by Type (Disposable Autoinjectors and Reusable Autoinjectors (Prefilled, and Empty)) and major geographies with country level break-up.

Research Analyst at AMA predicts that Players from European and United States will contribute to the maximum growth of Global Autoinjector market throughout the predicted period.

AbbVie Inc. (United States), Mylan (United States), Eli Lilly and Company (United States), Ypsomed (Switzerland), Amgen (United States), Becton, Dickinson, and Company (United States), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Teva Pharmaceutical (Israel), Antares Pharma (United States), Merck KGaA (Germany) and Bayer AG (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Bristol Myers Squibb (United States), SHL Medical (Switzerland), Haselmeier GmbH (Germany), Owen Mumford (United Kingdom) and Medeca Pharma AB (Sweden).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Autoinjector market by Type, Application and Region.

On the basis of geography, the market of Autoinjector has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their development strategies
In August 2020, Antares Pharma (US) signed an agreement with Lunatus Global Medical Supplies (Dubai). In this agreement, Antares will supply packaged products to Lunatus, and Lunatus will submit and obtain regulatory approval for XYOSTED in the UAE and Saudi Arabia as well as promote, market, and distribute XYOSTED in these two countries. and In March 2020, SHL Medical (Switzerland) acquired Weibel CDS (Switzerland). This acquisition aimed at strengthening SHL Medical’s ability to provide more advanced drug delivery systems based on human-centered designs and functionality.
In January 2020, Eli Lilly invested USD 470 million and created over 460 new jobs in Durham, NC. This expansion brought a new state-of-the-art pharmaceutical manufacturing facility to North Carolina’s research triangle park.


Influencing Market Trend
  • Availability of Generic Versions of Autoinjectors

Market Drivers
  • Increasing Prevalence of Targeted Therapies
  • Rising Incidence of Anaphylaxis across the Global
  • Growing Number of Regulatory Approvals

Opportunities
  • Patent Expiry of Biologics to Drive the Demand for Biosimilars

Restraints
  • Availability of Alternative Drug Delivery Modes
  • Research, Development, and Launch of Oral Diabetic Agents and Oral Insulin

Challenges
  • Lack of Proper Training for using Autoinjectors


Key Target Audience
Autoinjector Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Disposable Autoinjectors
  • Reusable Autoinjectors (Prefilled, and Empty)
By Therapy
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis
  • Others Therapies

By Route of Administration
  • Subcutaneous
  • Intramuscular

By End User
  • Home Care Settings
  • Hospitals & Clinics
  • Ambulatory Care Settings

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Targeted Therapies
      • 3.2.2. Rising Incidence of Anaphylaxis across the Global
      • 3.2.3. Growing Number of Regulatory Approvals
    • 3.3. Market Challenges
      • 3.3.1. Lack of Proper Training for using Autoinjectors
    • 3.4. Market Trends
      • 3.4.1. Availability of Generic Versions of Autoinjectors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Autoinjector, by Type, Therapy, Route of Administration, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Autoinjector (Value)
      • 5.2.1. Global Autoinjector by: Type (Value)
        • 5.2.1.1. Disposable Autoinjectors
        • 5.2.1.2. Reusable Autoinjectors (Prefilled, and Empty)
      • 5.2.2. Global Autoinjector by: Therapy (Value)
        • 5.2.2.1. Rheumatoid Arthritis
        • 5.2.2.2. Multiple Sclerosis
        • 5.2.2.3. Diabetes
        • 5.2.2.4. Anaphylaxis
        • 5.2.2.5. Others Therapies
      • 5.2.3. Global Autoinjector by: Route of Administration (Value)
        • 5.2.3.1. Subcutaneous
        • 5.2.3.2. Intramuscular
      • 5.2.4. Global Autoinjector by: End User (Value)
        • 5.2.4.1. Home Care Settings
        • 5.2.4.2. Hospitals & Clinics
        • 5.2.4.3. Ambulatory Care Settings
      • 5.2.5. Global Autoinjector Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Autoinjector (Volume)
      • 5.3.1. Global Autoinjector by: Type (Volume)
        • 5.3.1.1. Disposable Autoinjectors
        • 5.3.1.2. Reusable Autoinjectors (Prefilled, and Empty)
      • 5.3.2. Global Autoinjector by: Therapy (Volume)
        • 5.3.2.1. Rheumatoid Arthritis
        • 5.3.2.2. Multiple Sclerosis
        • 5.3.2.3. Diabetes
        • 5.3.2.4. Anaphylaxis
        • 5.3.2.5. Others Therapies
      • 5.3.3. Global Autoinjector by: Route of Administration (Volume)
        • 5.3.3.1. Subcutaneous
        • 5.3.3.2. Intramuscular
      • 5.3.4. Global Autoinjector by: End User (Volume)
        • 5.3.4.1. Home Care Settings
        • 5.3.4.2. Hospitals & Clinics
        • 5.3.4.3. Ambulatory Care Settings
      • 5.3.5. Global Autoinjector Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Autoinjector (Price)
      • 5.4.1. Global Autoinjector by: Type (Price)
  • 6. Autoinjector: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mylan (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ypsomed (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Becton, Dickinson, and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Antares Pharma (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Merck KGaA (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Bayer AG (Germany)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Autoinjector Sale, by Type, Therapy, Route of Administration, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Autoinjector (Value)
      • 7.2.1. Global Autoinjector by: Type (Value)
        • 7.2.1.1. Disposable Autoinjectors
        • 7.2.1.2. Reusable Autoinjectors (Prefilled, and Empty)
      • 7.2.2. Global Autoinjector by: Therapy (Value)
        • 7.2.2.1. Rheumatoid Arthritis
        • 7.2.2.2. Multiple Sclerosis
        • 7.2.2.3. Diabetes
        • 7.2.2.4. Anaphylaxis
        • 7.2.2.5. Others Therapies
      • 7.2.3. Global Autoinjector by: Route of Administration (Value)
        • 7.2.3.1. Subcutaneous
        • 7.2.3.2. Intramuscular
      • 7.2.4. Global Autoinjector by: End User (Value)
        • 7.2.4.1. Home Care Settings
        • 7.2.4.2. Hospitals & Clinics
        • 7.2.4.3. Ambulatory Care Settings
      • 7.2.5. Global Autoinjector Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Autoinjector (Volume)
      • 7.3.1. Global Autoinjector by: Type (Volume)
        • 7.3.1.1. Disposable Autoinjectors
        • 7.3.1.2. Reusable Autoinjectors (Prefilled, and Empty)
      • 7.3.2. Global Autoinjector by: Therapy (Volume)
        • 7.3.2.1. Rheumatoid Arthritis
        • 7.3.2.2. Multiple Sclerosis
        • 7.3.2.3. Diabetes
        • 7.3.2.4. Anaphylaxis
        • 7.3.2.5. Others Therapies
      • 7.3.3. Global Autoinjector by: Route of Administration (Volume)
        • 7.3.3.1. Subcutaneous
        • 7.3.3.2. Intramuscular
      • 7.3.4. Global Autoinjector by: End User (Volume)
        • 7.3.4.1. Home Care Settings
        • 7.3.4.2. Hospitals & Clinics
        • 7.3.4.3. Ambulatory Care Settings
      • 7.3.5. Global Autoinjector Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Autoinjector (Price)
      • 7.4.1. Global Autoinjector by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Autoinjector: by Type(USD Million)
  • Table 2. Autoinjector Disposable Autoinjectors , by Region USD Million (2015-2020)
  • Table 3. Autoinjector Reusable Autoinjectors (Prefilled, and Empty) , by Region USD Million (2015-2020)
  • Table 4. Autoinjector: by Therapy(USD Million)
  • Table 5. Autoinjector Rheumatoid Arthritis , by Region USD Million (2015-2020)
  • Table 6. Autoinjector Multiple Sclerosis , by Region USD Million (2015-2020)
  • Table 7. Autoinjector Diabetes , by Region USD Million (2015-2020)
  • Table 8. Autoinjector Anaphylaxis , by Region USD Million (2015-2020)
  • Table 9. Autoinjector Others Therapies , by Region USD Million (2015-2020)
  • Table 10. Autoinjector: by Route of Administration(USD Million)
  • Table 11. Autoinjector Subcutaneous , by Region USD Million (2015-2020)
  • Table 12. Autoinjector Intramuscular , by Region USD Million (2015-2020)
  • Table 13. Autoinjector: by End User(USD Million)
  • Table 14. Autoinjector Home Care Settings , by Region USD Million (2015-2020)
  • Table 15. Autoinjector Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 16. Autoinjector Ambulatory Care Settings , by Region USD Million (2015-2020)
  • Table 17. South America Autoinjector, by Country USD Million (2015-2020)
  • Table 18. South America Autoinjector, by Type USD Million (2015-2020)
  • Table 19. South America Autoinjector, by Therapy USD Million (2015-2020)
  • Table 20. South America Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 21. South America Autoinjector, by End User USD Million (2015-2020)
  • Table 22. Brazil Autoinjector, by Type USD Million (2015-2020)
  • Table 23. Brazil Autoinjector, by Therapy USD Million (2015-2020)
  • Table 24. Brazil Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 25. Brazil Autoinjector, by End User USD Million (2015-2020)
  • Table 26. Argentina Autoinjector, by Type USD Million (2015-2020)
  • Table 27. Argentina Autoinjector, by Therapy USD Million (2015-2020)
  • Table 28. Argentina Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 29. Argentina Autoinjector, by End User USD Million (2015-2020)
  • Table 30. Rest of South America Autoinjector, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Autoinjector, by Therapy USD Million (2015-2020)
  • Table 32. Rest of South America Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 33. Rest of South America Autoinjector, by End User USD Million (2015-2020)
  • Table 34. Asia Pacific Autoinjector, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Autoinjector, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Autoinjector, by Therapy USD Million (2015-2020)
  • Table 37. Asia Pacific Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 38. Asia Pacific Autoinjector, by End User USD Million (2015-2020)
  • Table 39. China Autoinjector, by Type USD Million (2015-2020)
  • Table 40. China Autoinjector, by Therapy USD Million (2015-2020)
  • Table 41. China Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 42. China Autoinjector, by End User USD Million (2015-2020)
  • Table 43. Japan Autoinjector, by Type USD Million (2015-2020)
  • Table 44. Japan Autoinjector, by Therapy USD Million (2015-2020)
  • Table 45. Japan Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 46. Japan Autoinjector, by End User USD Million (2015-2020)
  • Table 47. India Autoinjector, by Type USD Million (2015-2020)
  • Table 48. India Autoinjector, by Therapy USD Million (2015-2020)
  • Table 49. India Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 50. India Autoinjector, by End User USD Million (2015-2020)
  • Table 51. South Korea Autoinjector, by Type USD Million (2015-2020)
  • Table 52. South Korea Autoinjector, by Therapy USD Million (2015-2020)
  • Table 53. South Korea Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 54. South Korea Autoinjector, by End User USD Million (2015-2020)
  • Table 55. Taiwan Autoinjector, by Type USD Million (2015-2020)
  • Table 56. Taiwan Autoinjector, by Therapy USD Million (2015-2020)
  • Table 57. Taiwan Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 58. Taiwan Autoinjector, by End User USD Million (2015-2020)
  • Table 59. Australia Autoinjector, by Type USD Million (2015-2020)
  • Table 60. Australia Autoinjector, by Therapy USD Million (2015-2020)
  • Table 61. Australia Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 62. Australia Autoinjector, by End User USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Autoinjector, by Type USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Autoinjector, by Therapy USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Autoinjector, by End User USD Million (2015-2020)
  • Table 67. Europe Autoinjector, by Country USD Million (2015-2020)
  • Table 68. Europe Autoinjector, by Type USD Million (2015-2020)
  • Table 69. Europe Autoinjector, by Therapy USD Million (2015-2020)
  • Table 70. Europe Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 71. Europe Autoinjector, by End User USD Million (2015-2020)
  • Table 72. Germany Autoinjector, by Type USD Million (2015-2020)
  • Table 73. Germany Autoinjector, by Therapy USD Million (2015-2020)
  • Table 74. Germany Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 75. Germany Autoinjector, by End User USD Million (2015-2020)
  • Table 76. France Autoinjector, by Type USD Million (2015-2020)
  • Table 77. France Autoinjector, by Therapy USD Million (2015-2020)
  • Table 78. France Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 79. France Autoinjector, by End User USD Million (2015-2020)
  • Table 80. Italy Autoinjector, by Type USD Million (2015-2020)
  • Table 81. Italy Autoinjector, by Therapy USD Million (2015-2020)
  • Table 82. Italy Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 83. Italy Autoinjector, by End User USD Million (2015-2020)
  • Table 84. United Kingdom Autoinjector, by Type USD Million (2015-2020)
  • Table 85. United Kingdom Autoinjector, by Therapy USD Million (2015-2020)
  • Table 86. United Kingdom Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 87. United Kingdom Autoinjector, by End User USD Million (2015-2020)
  • Table 88. Netherlands Autoinjector, by Type USD Million (2015-2020)
  • Table 89. Netherlands Autoinjector, by Therapy USD Million (2015-2020)
  • Table 90. Netherlands Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 91. Netherlands Autoinjector, by End User USD Million (2015-2020)
  • Table 92. Rest of Europe Autoinjector, by Type USD Million (2015-2020)
  • Table 93. Rest of Europe Autoinjector, by Therapy USD Million (2015-2020)
  • Table 94. Rest of Europe Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 95. Rest of Europe Autoinjector, by End User USD Million (2015-2020)
  • Table 96. MEA Autoinjector, by Country USD Million (2015-2020)
  • Table 97. MEA Autoinjector, by Type USD Million (2015-2020)
  • Table 98. MEA Autoinjector, by Therapy USD Million (2015-2020)
  • Table 99. MEA Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 100. MEA Autoinjector, by End User USD Million (2015-2020)
  • Table 101. Middle East Autoinjector, by Type USD Million (2015-2020)
  • Table 102. Middle East Autoinjector, by Therapy USD Million (2015-2020)
  • Table 103. Middle East Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 104. Middle East Autoinjector, by End User USD Million (2015-2020)
  • Table 105. Africa Autoinjector, by Type USD Million (2015-2020)
  • Table 106. Africa Autoinjector, by Therapy USD Million (2015-2020)
  • Table 107. Africa Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 108. Africa Autoinjector, by End User USD Million (2015-2020)
  • Table 109. North America Autoinjector, by Country USD Million (2015-2020)
  • Table 110. North America Autoinjector, by Type USD Million (2015-2020)
  • Table 111. North America Autoinjector, by Therapy USD Million (2015-2020)
  • Table 112. North America Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 113. North America Autoinjector, by End User USD Million (2015-2020)
  • Table 114. United States Autoinjector, by Type USD Million (2015-2020)
  • Table 115. United States Autoinjector, by Therapy USD Million (2015-2020)
  • Table 116. United States Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 117. United States Autoinjector, by End User USD Million (2015-2020)
  • Table 118. Canada Autoinjector, by Type USD Million (2015-2020)
  • Table 119. Canada Autoinjector, by Therapy USD Million (2015-2020)
  • Table 120. Canada Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 121. Canada Autoinjector, by End User USD Million (2015-2020)
  • Table 122. Mexico Autoinjector, by Type USD Million (2015-2020)
  • Table 123. Mexico Autoinjector, by Therapy USD Million (2015-2020)
  • Table 124. Mexico Autoinjector, by Route of Administration USD Million (2015-2020)
  • Table 125. Mexico Autoinjector, by End User USD Million (2015-2020)
  • Table 126. Autoinjector Sales: by Type(Million Units)
  • Table 127. Autoinjector Sales Disposable Autoinjectors , by Region Million Units (2015-2020)
  • Table 128. Autoinjector Sales Reusable Autoinjectors (Prefilled, and Empty) , by Region Million Units (2015-2020)
  • Table 129. Autoinjector Sales: by Therapy(Million Units)
  • Table 130. Autoinjector Sales Rheumatoid Arthritis , by Region Million Units (2015-2020)
  • Table 131. Autoinjector Sales Multiple Sclerosis , by Region Million Units (2015-2020)
  • Table 132. Autoinjector Sales Diabetes , by Region Million Units (2015-2020)
  • Table 133. Autoinjector Sales Anaphylaxis , by Region Million Units (2015-2020)
  • Table 134. Autoinjector Sales Others Therapies , by Region Million Units (2015-2020)
  • Table 135. Autoinjector Sales: by Route of Administration(Million Units)
  • Table 136. Autoinjector Sales Subcutaneous , by Region Million Units (2015-2020)
  • Table 137. Autoinjector Sales Intramuscular , by Region Million Units (2015-2020)
  • Table 138. Autoinjector Sales: by End User(Million Units)
  • Table 139. Autoinjector Sales Home Care Settings , by Region Million Units (2015-2020)
  • Table 140. Autoinjector Sales Hospitals & Clinics , by Region Million Units (2015-2020)
  • Table 141. Autoinjector Sales Ambulatory Care Settings , by Region Million Units (2015-2020)
  • Table 142. South America Autoinjector Sales, by Country Million Units (2015-2020)
  • Table 143. South America Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 144. South America Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 145. South America Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 146. South America Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 147. Brazil Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 148. Brazil Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 149. Brazil Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 150. Brazil Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 151. Argentina Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 152. Argentina Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 153. Argentina Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 154. Argentina Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 155. Rest of South America Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 156. Rest of South America Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 157. Rest of South America Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 158. Rest of South America Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 159. Asia Pacific Autoinjector Sales, by Country Million Units (2015-2020)
  • Table 160. Asia Pacific Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 161. Asia Pacific Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 162. Asia Pacific Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 163. Asia Pacific Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 164. China Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 165. China Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 166. China Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 167. China Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 168. Japan Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 169. Japan Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 170. Japan Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 171. Japan Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 172. India Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 173. India Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 174. India Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 175. India Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 176. South Korea Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 177. South Korea Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 178. South Korea Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 179. South Korea Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 180. Taiwan Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 181. Taiwan Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 182. Taiwan Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 183. Taiwan Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 184. Australia Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 185. Australia Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 186. Australia Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 187. Australia Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 188. Rest of Asia-Pacific Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 189. Rest of Asia-Pacific Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 190. Rest of Asia-Pacific Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 191. Rest of Asia-Pacific Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 192. Europe Autoinjector Sales, by Country Million Units (2015-2020)
  • Table 193. Europe Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 194. Europe Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 195. Europe Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 196. Europe Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 197. Germany Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 198. Germany Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 199. Germany Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 200. Germany Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 201. France Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 202. France Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 203. France Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 204. France Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 205. Italy Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 206. Italy Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 207. Italy Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 208. Italy Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 209. United Kingdom Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 210. United Kingdom Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 211. United Kingdom Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 212. United Kingdom Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 213. Netherlands Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 214. Netherlands Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 215. Netherlands Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 216. Netherlands Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 217. Rest of Europe Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 218. Rest of Europe Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 219. Rest of Europe Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 220. Rest of Europe Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 221. MEA Autoinjector Sales, by Country Million Units (2015-2020)
  • Table 222. MEA Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 223. MEA Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 224. MEA Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 225. MEA Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 226. Middle East Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 227. Middle East Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 228. Middle East Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 229. Middle East Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 230. Africa Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 231. Africa Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 232. Africa Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 233. Africa Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 234. North America Autoinjector Sales, by Country Million Units (2015-2020)
  • Table 235. North America Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 236. North America Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 237. North America Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 238. North America Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 239. United States Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 240. United States Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 241. United States Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 242. United States Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 243. Canada Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 244. Canada Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 245. Canada Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 246. Canada Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 247. Mexico Autoinjector Sales, by Type Million Units (2015-2020)
  • Table 248. Mexico Autoinjector Sales, by Therapy Million Units (2015-2020)
  • Table 249. Mexico Autoinjector Sales, by Route of Administration Million Units (2015-2020)
  • Table 250. Mexico Autoinjector Sales, by End User Million Units (2015-2020)
  • Table 251. Autoinjector: by Type(USD/Units)
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Autoinjector: by Type(USD Million)
  • Table 265. Autoinjector Disposable Autoinjectors , by Region USD Million (2021-2026)
  • Table 266. Autoinjector Reusable Autoinjectors (Prefilled, and Empty) , by Region USD Million (2021-2026)
  • Table 267. Autoinjector: by Therapy(USD Million)
  • Table 268. Autoinjector Rheumatoid Arthritis , by Region USD Million (2021-2026)
  • Table 269. Autoinjector Multiple Sclerosis , by Region USD Million (2021-2026)
  • Table 270. Autoinjector Diabetes , by Region USD Million (2021-2026)
  • Table 271. Autoinjector Anaphylaxis , by Region USD Million (2021-2026)
  • Table 272. Autoinjector Others Therapies , by Region USD Million (2021-2026)
  • Table 273. Autoinjector: by Route of Administration(USD Million)
  • Table 274. Autoinjector Subcutaneous , by Region USD Million (2021-2026)
  • Table 275. Autoinjector Intramuscular , by Region USD Million (2021-2026)
  • Table 276. Autoinjector: by End User(USD Million)
  • Table 277. Autoinjector Home Care Settings , by Region USD Million (2021-2026)
  • Table 278. Autoinjector Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 279. Autoinjector Ambulatory Care Settings , by Region USD Million (2021-2026)
  • Table 280. South America Autoinjector, by Country USD Million (2021-2026)
  • Table 281. South America Autoinjector, by Type USD Million (2021-2026)
  • Table 282. South America Autoinjector, by Therapy USD Million (2021-2026)
  • Table 283. South America Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 284. South America Autoinjector, by End User USD Million (2021-2026)
  • Table 285. Brazil Autoinjector, by Type USD Million (2021-2026)
  • Table 286. Brazil Autoinjector, by Therapy USD Million (2021-2026)
  • Table 287. Brazil Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 288. Brazil Autoinjector, by End User USD Million (2021-2026)
  • Table 289. Argentina Autoinjector, by Type USD Million (2021-2026)
  • Table 290. Argentina Autoinjector, by Therapy USD Million (2021-2026)
  • Table 291. Argentina Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 292. Argentina Autoinjector, by End User USD Million (2021-2026)
  • Table 293. Rest of South America Autoinjector, by Type USD Million (2021-2026)
  • Table 294. Rest of South America Autoinjector, by Therapy USD Million (2021-2026)
  • Table 295. Rest of South America Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 296. Rest of South America Autoinjector, by End User USD Million (2021-2026)
  • Table 297. Asia Pacific Autoinjector, by Country USD Million (2021-2026)
  • Table 298. Asia Pacific Autoinjector, by Type USD Million (2021-2026)
  • Table 299. Asia Pacific Autoinjector, by Therapy USD Million (2021-2026)
  • Table 300. Asia Pacific Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 301. Asia Pacific Autoinjector, by End User USD Million (2021-2026)
  • Table 302. China Autoinjector, by Type USD Million (2021-2026)
  • Table 303. China Autoinjector, by Therapy USD Million (2021-2026)
  • Table 304. China Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 305. China Autoinjector, by End User USD Million (2021-2026)
  • Table 306. Japan Autoinjector, by Type USD Million (2021-2026)
  • Table 307. Japan Autoinjector, by Therapy USD Million (2021-2026)
  • Table 308. Japan Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 309. Japan Autoinjector, by End User USD Million (2021-2026)
  • Table 310. India Autoinjector, by Type USD Million (2021-2026)
  • Table 311. India Autoinjector, by Therapy USD Million (2021-2026)
  • Table 312. India Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 313. India Autoinjector, by End User USD Million (2021-2026)
  • Table 314. South Korea Autoinjector, by Type USD Million (2021-2026)
  • Table 315. South Korea Autoinjector, by Therapy USD Million (2021-2026)
  • Table 316. South Korea Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 317. South Korea Autoinjector, by End User USD Million (2021-2026)
  • Table 318. Taiwan Autoinjector, by Type USD Million (2021-2026)
  • Table 319. Taiwan Autoinjector, by Therapy USD Million (2021-2026)
  • Table 320. Taiwan Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 321. Taiwan Autoinjector, by End User USD Million (2021-2026)
  • Table 322. Australia Autoinjector, by Type USD Million (2021-2026)
  • Table 323. Australia Autoinjector, by Therapy USD Million (2021-2026)
  • Table 324. Australia Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 325. Australia Autoinjector, by End User USD Million (2021-2026)
  • Table 326. Rest of Asia-Pacific Autoinjector, by Type USD Million (2021-2026)
  • Table 327. Rest of Asia-Pacific Autoinjector, by Therapy USD Million (2021-2026)
  • Table 328. Rest of Asia-Pacific Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 329. Rest of Asia-Pacific Autoinjector, by End User USD Million (2021-2026)
  • Table 330. Europe Autoinjector, by Country USD Million (2021-2026)
  • Table 331. Europe Autoinjector, by Type USD Million (2021-2026)
  • Table 332. Europe Autoinjector, by Therapy USD Million (2021-2026)
  • Table 333. Europe Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 334. Europe Autoinjector, by End User USD Million (2021-2026)
  • Table 335. Germany Autoinjector, by Type USD Million (2021-2026)
  • Table 336. Germany Autoinjector, by Therapy USD Million (2021-2026)
  • Table 337. Germany Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 338. Germany Autoinjector, by End User USD Million (2021-2026)
  • Table 339. France Autoinjector, by Type USD Million (2021-2026)
  • Table 340. France Autoinjector, by Therapy USD Million (2021-2026)
  • Table 341. France Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 342. France Autoinjector, by End User USD Million (2021-2026)
  • Table 343. Italy Autoinjector, by Type USD Million (2021-2026)
  • Table 344. Italy Autoinjector, by Therapy USD Million (2021-2026)
  • Table 345. Italy Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 346. Italy Autoinjector, by End User USD Million (2021-2026)
  • Table 347. United Kingdom Autoinjector, by Type USD Million (2021-2026)
  • Table 348. United Kingdom Autoinjector, by Therapy USD Million (2021-2026)
  • Table 349. United Kingdom Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 350. United Kingdom Autoinjector, by End User USD Million (2021-2026)
  • Table 351. Netherlands Autoinjector, by Type USD Million (2021-2026)
  • Table 352. Netherlands Autoinjector, by Therapy USD Million (2021-2026)
  • Table 353. Netherlands Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 354. Netherlands Autoinjector, by End User USD Million (2021-2026)
  • Table 355. Rest of Europe Autoinjector, by Type USD Million (2021-2026)
  • Table 356. Rest of Europe Autoinjector, by Therapy USD Million (2021-2026)
  • Table 357. Rest of Europe Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 358. Rest of Europe Autoinjector, by End User USD Million (2021-2026)
  • Table 359. MEA Autoinjector, by Country USD Million (2021-2026)
  • Table 360. MEA Autoinjector, by Type USD Million (2021-2026)
  • Table 361. MEA Autoinjector, by Therapy USD Million (2021-2026)
  • Table 362. MEA Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 363. MEA Autoinjector, by End User USD Million (2021-2026)
  • Table 364. Middle East Autoinjector, by Type USD Million (2021-2026)
  • Table 365. Middle East Autoinjector, by Therapy USD Million (2021-2026)
  • Table 366. Middle East Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 367. Middle East Autoinjector, by End User USD Million (2021-2026)
  • Table 368. Africa Autoinjector, by Type USD Million (2021-2026)
  • Table 369. Africa Autoinjector, by Therapy USD Million (2021-2026)
  • Table 370. Africa Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 371. Africa Autoinjector, by End User USD Million (2021-2026)
  • Table 372. North America Autoinjector, by Country USD Million (2021-2026)
  • Table 373. North America Autoinjector, by Type USD Million (2021-2026)
  • Table 374. North America Autoinjector, by Therapy USD Million (2021-2026)
  • Table 375. North America Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 376. North America Autoinjector, by End User USD Million (2021-2026)
  • Table 377. United States Autoinjector, by Type USD Million (2021-2026)
  • Table 378. United States Autoinjector, by Therapy USD Million (2021-2026)
  • Table 379. United States Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 380. United States Autoinjector, by End User USD Million (2021-2026)
  • Table 381. Canada Autoinjector, by Type USD Million (2021-2026)
  • Table 382. Canada Autoinjector, by Therapy USD Million (2021-2026)
  • Table 383. Canada Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 384. Canada Autoinjector, by End User USD Million (2021-2026)
  • Table 385. Mexico Autoinjector, by Type USD Million (2021-2026)
  • Table 386. Mexico Autoinjector, by Therapy USD Million (2021-2026)
  • Table 387. Mexico Autoinjector, by Route of Administration USD Million (2021-2026)
  • Table 388. Mexico Autoinjector, by End User USD Million (2021-2026)
  • Table 389. Autoinjector Sales: by Type(Million Units)
  • Table 390. Autoinjector Sales Disposable Autoinjectors , by Region Million Units (2021-2026)
  • Table 391. Autoinjector Sales Reusable Autoinjectors (Prefilled, and Empty) , by Region Million Units (2021-2026)
  • Table 392. Autoinjector Sales: by Therapy(Million Units)
  • Table 393. Autoinjector Sales Rheumatoid Arthritis , by Region Million Units (2021-2026)
  • Table 394. Autoinjector Sales Multiple Sclerosis , by Region Million Units (2021-2026)
  • Table 395. Autoinjector Sales Diabetes , by Region Million Units (2021-2026)
  • Table 396. Autoinjector Sales Anaphylaxis , by Region Million Units (2021-2026)
  • Table 397. Autoinjector Sales Others Therapies , by Region Million Units (2021-2026)
  • Table 398. Autoinjector Sales: by Route of Administration(Million Units)
  • Table 399. Autoinjector Sales Subcutaneous , by Region Million Units (2021-2026)
  • Table 400. Autoinjector Sales Intramuscular , by Region Million Units (2021-2026)
  • Table 401. Autoinjector Sales: by End User(Million Units)
  • Table 402. Autoinjector Sales Home Care Settings , by Region Million Units (2021-2026)
  • Table 403. Autoinjector Sales Hospitals & Clinics , by Region Million Units (2021-2026)
  • Table 404. Autoinjector Sales Ambulatory Care Settings , by Region Million Units (2021-2026)
  • Table 405. South America Autoinjector Sales, by Country Million Units (2021-2026)
  • Table 406. South America Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 407. South America Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 408. South America Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 409. South America Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 410. Brazil Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 411. Brazil Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 412. Brazil Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 413. Brazil Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 414. Argentina Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 415. Argentina Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 416. Argentina Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 417. Argentina Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 418. Rest of South America Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 419. Rest of South America Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 420. Rest of South America Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 421. Rest of South America Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 422. Asia Pacific Autoinjector Sales, by Country Million Units (2021-2026)
  • Table 423. Asia Pacific Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 424. Asia Pacific Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 425. Asia Pacific Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 426. Asia Pacific Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 427. China Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 428. China Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 429. China Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 430. China Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 431. Japan Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 432. Japan Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 433. Japan Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 434. Japan Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 435. India Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 436. India Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 437. India Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 438. India Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 439. South Korea Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 440. South Korea Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 441. South Korea Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 442. South Korea Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 443. Taiwan Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 444. Taiwan Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 445. Taiwan Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 446. Taiwan Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 447. Australia Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 448. Australia Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 449. Australia Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 450. Australia Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 451. Rest of Asia-Pacific Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 452. Rest of Asia-Pacific Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 453. Rest of Asia-Pacific Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 454. Rest of Asia-Pacific Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 455. Europe Autoinjector Sales, by Country Million Units (2021-2026)
  • Table 456. Europe Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 457. Europe Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 458. Europe Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 459. Europe Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 460. Germany Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 461. Germany Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 462. Germany Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 463. Germany Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 464. France Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 465. France Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 466. France Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 467. France Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 468. Italy Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 469. Italy Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 470. Italy Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 471. Italy Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 472. United Kingdom Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 473. United Kingdom Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 474. United Kingdom Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 475. United Kingdom Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 476. Netherlands Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 477. Netherlands Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 478. Netherlands Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 479. Netherlands Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 480. Rest of Europe Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 481. Rest of Europe Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 482. Rest of Europe Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 483. Rest of Europe Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 484. MEA Autoinjector Sales, by Country Million Units (2021-2026)
  • Table 485. MEA Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 486. MEA Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 487. MEA Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 488. MEA Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 489. Middle East Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 490. Middle East Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 491. Middle East Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 492. Middle East Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 493. Africa Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 494. Africa Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 495. Africa Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 496. Africa Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 497. North America Autoinjector Sales, by Country Million Units (2021-2026)
  • Table 498. North America Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 499. North America Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 500. North America Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 501. North America Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 502. United States Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 503. United States Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 504. United States Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 505. United States Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 506. Canada Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 507. Canada Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 508. Canada Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 509. Canada Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 510. Mexico Autoinjector Sales, by Type Million Units (2021-2026)
  • Table 511. Mexico Autoinjector Sales, by Therapy Million Units (2021-2026)
  • Table 512. Mexico Autoinjector Sales, by Route of Administration Million Units (2021-2026)
  • Table 513. Mexico Autoinjector Sales, by End User Million Units (2021-2026)
  • Table 514. Autoinjector: by Type(USD/Units)
  • Table 515. Research Programs/Design for This Report
  • Table 516. Key Data Information from Secondary Sources
  • Table 517. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Autoinjector: by Type USD Million (2015-2020)
  • Figure 5. Global Autoinjector: by Therapy USD Million (2015-2020)
  • Figure 6. Global Autoinjector: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Autoinjector: by End User USD Million (2015-2020)
  • Figure 8. South America Autoinjector Share (%), by Country
  • Figure 9. Asia Pacific Autoinjector Share (%), by Country
  • Figure 10. Europe Autoinjector Share (%), by Country
  • Figure 11. MEA Autoinjector Share (%), by Country
  • Figure 12. North America Autoinjector Share (%), by Country
  • Figure 13. Global Autoinjector: by Type Million Units (2015-2020)
  • Figure 14. Global Autoinjector: by Therapy Million Units (2015-2020)
  • Figure 15. Global Autoinjector: by Route of Administration Million Units (2015-2020)
  • Figure 16. Global Autoinjector: by End User Million Units (2015-2020)
  • Figure 17. South America Autoinjector Share (%), by Country
  • Figure 18. Asia Pacific Autoinjector Share (%), by Country
  • Figure 19. Europe Autoinjector Share (%), by Country
  • Figure 20. MEA Autoinjector Share (%), by Country
  • Figure 21. North America Autoinjector Share (%), by Country
  • Figure 22. Global Autoinjector: by Type USD/Units (2015-2020)
  • Figure 23. Global Autoinjector share by Players 2020 (%)
  • Figure 24. Global Autoinjector share by Players (Top 3) 2020(%)
  • Figure 25. Global Autoinjector share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan (United States) Revenue: by Geography 2020
  • Figure 31. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 33. Ypsomed (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Ypsomed (Switzerland) Revenue: by Geography 2020
  • Figure 35. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amgen (United States) Revenue: by Geography 2020
  • Figure 37. Becton, Dickinson, and Company (United States) Revenue, Net Income and Gross profit
  • Figure 38. Becton, Dickinson, and Company (United States) Revenue: by Geography 2020
  • Figure 39. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 41. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 42. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 43. Teva Pharmaceutical (Israel) Revenue, Net Income and Gross profit
  • Figure 44. Teva Pharmaceutical (Israel) Revenue: by Geography 2020
  • Figure 45. Antares Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 46. Antares Pharma (United States) Revenue: by Geography 2020
  • Figure 47. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 48. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 49. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 50. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 51. Global Autoinjector: by Type USD Million (2021-2026)
  • Figure 52. Global Autoinjector: by Therapy USD Million (2021-2026)
  • Figure 53. Global Autoinjector: by Route of Administration USD Million (2021-2026)
  • Figure 54. Global Autoinjector: by End User USD Million (2021-2026)
  • Figure 55. South America Autoinjector Share (%), by Country
  • Figure 56. Asia Pacific Autoinjector Share (%), by Country
  • Figure 57. Europe Autoinjector Share (%), by Country
  • Figure 58. MEA Autoinjector Share (%), by Country
  • Figure 59. North America Autoinjector Share (%), by Country
  • Figure 60. Global Autoinjector: by Type Million Units (2021-2026)
  • Figure 61. Global Autoinjector: by Therapy Million Units (2021-2026)
  • Figure 62. Global Autoinjector: by Route of Administration Million Units (2021-2026)
  • Figure 63. Global Autoinjector: by End User Million Units (2021-2026)
  • Figure 64. South America Autoinjector Share (%), by Country
  • Figure 65. Asia Pacific Autoinjector Share (%), by Country
  • Figure 66. Europe Autoinjector Share (%), by Country
  • Figure 67. MEA Autoinjector Share (%), by Country
  • Figure 68. North America Autoinjector Share (%), by Country
  • Figure 69. Global Autoinjector: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • AbbVie Inc. (United States)
  • Mylan (United States)
  • Eli Lilly and Company (United States)
  • Ypsomed (Switzerland)
  • Amgen (United States)
  • Becton, Dickinson, and Company (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Johnson & Johnson (United States)
  • Teva Pharmaceutical (Israel)
  • Antares Pharma (United States)
  • Merck KGaA (Germany)
  • Bayer AG (Germany)
Additional players considered in the study are as follows:
Bristol Myers Squibb (United States) , SHL Medical (Switzerland) , Haselmeier GmbH (Germany) , Owen Mumford (United Kingdom) , Medeca Pharma AB (Sweden)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation